Jasper Therapeutics promotes Mahal to COO, Heller to exit, new CMO role created

Jasper Therapeutics, Inc.

Jeet Mahal promoted to COO (retains CFO); salary raised to $445,000, bonus target 45%.
Kevin Heller's employment ends May 17, 2022; consulting through March 2023 at ~$37,939/month plus COBRA.
Wendy Pang promoted to SVP of Research and Translational Medicine, effective March 21, 2022.
New Chief Medical Officer position created; active search underway. Judith Shizuru leads clinical interim.
All changes effective March 21, 2022, except Heller's separation date May 17, 2022.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kevin N. Heller

Executive Vice President, Research and Development

JSPR · Jasper Therapeutics, Inc.

Effective: 2022-05-17
Filed: March 21, 2022, 7:59 PM ET

Dr. Heller’s employment with the Company will terminate, effective May 17, 2022.

Role change

Jeet Mahal

Chief Operating Officer and Chief Financial Officer

JSPR · Jasper Therapeutics, Inc.

Effective: 2022-03-21
Filed: March 21, 2022, 7:59 PM ET

On March 18, 2022, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) approved the promotion of Jeet Mahal, age 50, the Company’s Chief Financial Officer and Chief Business Officer, to Chief Operating Officer and Chief Financial Officer, effective March 21, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin N. Heller was terminated as Executive Vice President, Research and Development at Jasper Therapeutics, Inc..

Action: terminated
Role: Executive Vice President, Research and Development

Exact text from the filing

Dr. Heller’s employment with the Company will terminate, effective May 17, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeet Mahal changed role as Chief Operating Officer and Chief Financial Officer at Jasper Therapeutics, Inc..

Action: promoted
Role: Chief Operating Officer and Chief Financial Officer

Exact text from the filing

On March 18, 2022, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) approved the promotion of Jeet Mahal, age 50, the Company’s Chief Financial Officer and Chief Business Officer, to Chief Operating Officer and Chief Financial Officer, effective March 21, 2022.

View on SEC.gov

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-013743

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.